Testicular germ cell tumors: the changing role of the pathologist.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The ductal network in the human testis and epididymis: What belongs to which?Clinical anatomy (New York, N.Y.) · 2025
   Review
2. Gonadal Teratomas: A State-of-the-Art Review in Pathology.Cancers · 2024
   Review
3. Testicular cancer in mice: interplay between stem cells and endocrine insults.Stem cell research & therapy · 2022
   Article
4. The utility of cfDNA in TGCT patient management: a systematic review.Therapeutic advances in medical oncology · 2022
   Review
5. Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives.Cancers · 2020
   Review

Corrections and comments

• Comment on
  Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists.2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.